Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07657780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-65 years) with Severe Hypertriglyceridemia(sHTG).
Trial Details
NCT Number NCT07657780
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: The First Affiliated Hospital of Anhui Medical University
Conditions
(from sponsor)		 Severe Hypertriglyceridemia (sHTG)
Related terms Hypertriglyceridemia
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov